"Mercaptopurine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
| Descriptor ID |
D015122
|
| MeSH Number(s) |
D02.886.489.534 D03.633.100.759.534
|
| Concept/Terms |
Mercaptopurine- Mercaptopurine
- 6-Thiopurine
- 6 Thiopurine
- 6-Mercaptopurine Monohydrate
- 6 Mercaptopurine Monohydrate
- 1,7-Dihydro-6H-purine-6-thione
- 6-Thiohypoxanthine
- 6 Thiohypoxanthine
|
Below are MeSH descriptors whose meaning is more general than "Mercaptopurine".
Below are MeSH descriptors whose meaning is more specific than "Mercaptopurine".
This graph shows the total number of publications written about "Mercaptopurine" by people in this website by year, and whether "Mercaptopurine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 3 | 3 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2004 | 3 | 1 | 4 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 3 | 3 |
| 2007 | 1 | 1 | 2 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2013 | 2 | 2 | 4 |
| 2014 | 0 | 2 | 2 |
| 2018 | 2 | 1 | 3 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 1 | 0 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mercaptopurine" by people in Profiles.
-
A modified CALGB 10403 in adolescents and young adults with acute lymphoblastic leukemia in Central America. Blood Adv. 2023 09 26; 7(18):5202-5209.
-
Race, Genotype, and Azathioprine Discontinuation : A Cohort Study. Ann Intern Med. 2022 08; 175(8):1092-1099.
-
Omacetaxine added to a standard acute myeloid leukaemia chemotherapy regimen reduces cellular FLIP levels, markedly increasing the incidence of eccrine hidradenitis. Br J Haematol. 2021 11; 195(3):e138-e141.
-
Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease. Gastroenterology. 2021 03; 160(4):1131-1139.
-
Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary. Gastroenterology. 2019 01; 156(1):36-42.
-
Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases. J Clin Gastroenterol. 2018 07; 52(6):537-544.
-
Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study). Aliment Pharmacol Ther. 2018 Apr; 47(8):1092-1102.
-
The potential for medical therapy to reduce the risk of colorectal cancer and optimize surveillance in inflammatory bowel disease. Gastrointest Endosc Clin N Am. 2014 Jul; 24(3):353-65.
-
Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. Br J Haematol. 2014 May; 165(4):497-503.
-
American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-a biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology. 2013 Dec; 145(6):1464-78.e1-5.